Sawa M - Search Results

1

Compound Selectivity and Target Residence Time of Kinase Inhibitors Studied with Surface Plasmon Resonance.

Willemsen-Seegers N, Uitdehaag JCM, Prinsen MBW, de Vetter JRF, de Man J, Sawa M, Kawase Y, Buijsman RC, Zaman GJR. Willemsen-Seegers N, et al. Among authors: sawa m. J Mol Biol. 2017 Feb 17;429(4):574-586. doi: 10.1016/j.jmb.2016.12.019. Epub 2016 Dec 30. J Mol Biol. 2017. PMID: 28043854

2

Cell Panel Profiling Reveals Conserved Therapeutic Clusters and Differentiates the Mechanism of Action of Different PI3K/mTOR, Aurora Kinase and EZH2 Inhibitors.

Uitdehaag JC, de Roos JA, Prinsen MB, Willemsen-Seegers N, de Vetter JR, Dylus J, van Doornmalen AM, Kooijman J, Sawa M, van Gerwen SJ, de Man J, Buijsman RC, Zaman GJ. Uitdehaag JC, et al. Among authors: sawa m. Mol Cancer Ther. 2016 Dec;15(12):3097-3109. doi: 10.1158/1535-7163.MCT-16-0403. Epub 2016 Sep 1. Mol Cancer Ther. 2016. PMID: 27587489

3

Discovery of novel furanone derivatives as potent Cdc7 kinase inhibitors.

Irie T, Asami T, Sawa A, Uno Y, Hanada M, Taniyama C, Funakoshi Y, Masai H, Sawa M. Irie T, et al. Among authors: sawa a, sawa m. Eur J Med Chem. 2017 Apr 21;130:406-418. doi: 10.1016/j.ejmech.2017.02.030. Epub 2017 Feb 17. Eur J Med Chem. 2017. PMID: 28279847

4

7-Azaindole: A Versatile Scaffold for Developing Kinase Inhibitors.

Irie T, Sawa M. Irie T, et al. Among authors: sawa m. Chem Pharm Bull (Tokyo). 2018;66(1):29-36. doi: 10.1248/cpb.c17-00380. Chem Pharm Bull (Tokyo). 2018. PMID: 29311509 Free article. Review.

5

Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017.

Uitdehaag JCM, Kooijman JJ, de Roos JADM, Prinsen MBW, Dylus J, Willemsen-Seegers N, Kawase Y, Sawa M, de Man J, van Gerwen SJC, Buijsman RC, Zaman GJR. Uitdehaag JCM, et al. Among authors: sawa m. Mol Cancer Ther. 2019 Feb;18(2):470-481. doi: 10.1158/1535-7163.MCT-18-0877. Epub 2018 Oct 31. Mol Cancer Ther. 2019. PMID: 30381447

6

Strategies for the design of selective protein kinase inhibitors.

Sawa M. Sawa M. Mini Rev Med Chem. 2008 Oct;8(12):1291-7. doi: 10.2174/138955708786141043. Mini Rev Med Chem. 2008. PMID: 18855742 Review.

7

'Turn On/Off' fluorescence probe for the screening of unactivated Bruton's tyrosine kinase.

Kawahata W, Asami T, Fujii I, Sawa M. Kawahata W, et al. Among authors: sawa m. Bioorg Med Chem Lett. 2015;25(10):2141-5. doi: 10.1016/j.bmcl.2015.03.063. Epub 2015 Mar 30. Bioorg Med Chem Lett. 2015. PMID: 25843639

8

Design and synthesis of novel pyrimidine analogs as highly selective, non-covalent BTK inhibitors.

Kawahata W, Asami T, Irie T, Sawa M. Kawahata W, et al. Among authors: sawa m. Bioorg Med Chem Lett. 2018 Jan 15;28(2):145-151. doi: 10.1016/j.bmcl.2017.11.037. Epub 2017 Nov 24. Bioorg Med Chem Lett. 2018. PMID: 29198867

9

Design and Synthesis of Novel Amino-triazine Analogues as Selective Bruton's Tyrosine Kinase Inhibitors for Treatment of Rheumatoid Arthritis.

Kawahata W, Asami T, Kiyoi T, Irie T, Taniguchi H, Asamitsu Y, Inoue T, Miyake T, Sawa M. Kawahata W, et al. Among authors: sawa m. J Med Chem. 2018 Oct 11;61(19):8917-8933. doi: 10.1021/acs.jmedchem.8b01147. Epub 2018 Sep 28. J Med Chem. 2018. PMID: 30216722

10

A promiscuous kinase inhibitor delineates the conspicuous structural features of protein kinase CK2a1.

Tsuyuguchi M, Nakaniwa T, Sawa M, Nakanishi I, Kinoshita T. Tsuyuguchi M, et al. Among authors: sawa m. Acta Crystallogr F Struct Biol Commun. 2019 Jul 1;75(Pt 7):515-519. doi: 10.1107/S2053230X19008951. Epub 2019 Jul 4. Acta Crystallogr F Struct Biol Commun. 2019. PMID: 31282872 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

634 results

Search Page

Filters